{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:00:07Z","timestamp":1790805607345,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder characterized by the degeneration of upper and lower motor neurons, leading to progressive muscle weakness, paralysis, and respiratory failure. The recently proposed combination therapy consisting of celecoxib and ciprofloxacin hydrochloride has emerged as a potential treatment for amyotrophic lateral sclerosis and other neurodegenerative disorders. The present study aimed to develop and validate simple, sensitive, environmentally friendly, and cost-effective analytical methods for the simultaneous determination of celecoxib and ciprofloxacin hydrochloride in bulk powders, laboratory-prepared tablets and plasma. Two ultraviolet spectrophotometric methods were established. The first method relies on direct absorbance measurements of ciprofloxacin hydrochloride at 318\u00a0nm and celecoxib at the isosbestic point at 266\u00a0nm, while the second one employs first-derivative ratio spectrophotometry for the selective determination of ciprofloxacin hydrochloride and celecoxib at 280\u00a0nm and 254\u00a0nm, respectively. Moreover, a reversed-phase high-performance liquid chromatographic method was developed using a C18 stationary phase, an optimized mobile phase composition and both diode array and fluorescence detectors, achieving efficient separation and accurate quantification of both analytes. The developed procedures were successfully applied to laboratory-prepared tablets and plasma following optimization of the sample preparation protocol to minimize matrix interference and to improve analytes recovery. Validation results showed excellent linearity over the investigated concentration ranges together with satisfactory accuracy, precision, selectivity, and sensitivity, confirming the reliability of the proposed methods for routine quality control and bioanalytical applications. The overall analytical performance and environmental sustainability of the developed methods were further assessed using the environmental performance and practicality Index framework, demonstrating their suitability as reliable and sustainable analytical approaches for the determination of celecoxib and ciprofloxacin hydrochloride.<\/jats:p>","DOI":"10.1038\/s41598-026-66936-w","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:35:04Z","timestamp":1787218504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Green analytical methods for quantification of a new combination therapy for amyotrophic lateral sclerosis: assessment by EPPI framework"],"prefix":"10.1038","volume":"16","author":[{"given":"Faten M.","family":"Aboukhalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam F.","family":"Khamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha M.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira F.","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"66936_CR1","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 2662, C.R.N., 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Celecoxib (2025)."},{"issue":"4","key":"66936_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","volume":"22","author":"L Gong","year":"2012","unstructured":"Gong, L. et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics. 22 (4), 310\u2013318 (2012).","journal-title":"Pharmacogenet. Genomics"},{"key":"66936_CR3","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 44350862, C.H.A.F.I.R.N., 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ciprfloxacin-Hydrochloride-Anhydrous-Form-I (2025)."},{"issue":"3","key":"66936_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/clinids\/10.3.528","volume":"10","author":"WE Sanders Jr","year":"1988","unstructured":"Sanders, W. E. Jr Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev. Infect. Dis. 10 (3), 528\u2013543 (1988).","journal-title":"Rev. Infect. Dis."},{"issue":"1","key":"66936_CR5","first-page":"1","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. reviews Disease primers. 3 (1), 1\u201319 (2017).","journal-title":"Nat. reviews Disease primers"},{"key":"66936_CR6","unstructured":"Meglio, M. ALS Candidate PrimeC Meets Primary Safety and Secondary End Points in Phase 2b PARADIGM Study. Neurology Live, : p. NA-NA. (2023)."},{"issue":"4","key":"66936_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/ph18040524","volume":"18","author":"S Salomon-Zimri","year":"2025","unstructured":"Salomon-Zimri, S. et al. Elucidating The Synergistic Effect of the PrimeC Combination for Amyotrophic Lateral Sclerosis in iPSC and Mouse Models. Pharmaceuticals (Basel). 18 (4), 524. https:\/\/doi.org\/10.3390\/ph18040524 (2025).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9769","key":"66936_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377 (9769), 942\u2013955 (2011).","journal-title":"Lancet"},{"issue":"sup1","key":"66936_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678421.2017.1361447","volume":"18","author":"RG Miller","year":"2017","unstructured":"Miller, R. G. & Appel, S. H. Introduction to supplement: The current status of treatment for ALS. Amyotroph. Lateral Scler. Frontotemporal Degeneration. 18 (sup1), 1\u20134 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degeneration"},{"issue":"6","key":"66936_CR10","doi-asserted-by":"publisher","first-page":"e70222","DOI":"10.1002\/bio.70222","volume":"40","author":"AB Ahmed","year":"2025","unstructured":"Ahmed, A. B. et al. Innovative Synchronous Spectrofluorometric Method for Assessing a Novel Drug Combination in Amyotrophic Lateral Sclerosis: In Vivo Human Application With Greenness and Sustainability Evaluation. Luminescence 40 (6), e70222 (2025).","journal-title":"Luminescence"},{"issue":"1\u20132","key":"66936_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0021-9673(97)00966-7","volume":"797","author":"R Oertel","year":"1998","unstructured":"Oertel, R. et al. Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing. J. Chromatogr. A. 797 (1\u20132), 203\u2013209 (1998).","journal-title":"J. Chromatogr. A"},{"key":"66936_CR12","doi-asserted-by":"publisher","first-page":"100306","DOI":"10.1016\/j.greeac.2025.100306","volume":"15","author":"SH Elagamy","year":"2025","unstructured":"Elagamy, S. H. et al. EPPI: A comprehensive index framework for assessment of sustainability performance, and practicality of analytical methods. Green. Anal. Chem. 15, 100306 (2025).","journal-title":"Green. Anal. Chem."},{"key":"66936_CR13","doi-asserted-by":"crossref","unstructured":"Ermer, J. ICH Q2 (R2): validation of analytical procedures. Method validation in pharmaceutical analysis: a guide to best practice,: pp. 351\u2013372. (2025).","DOI":"10.1002\/9783527831708.ch13"},{"issue":"10","key":"66936_CR14","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1039\/C3AY42232A","volume":"6","author":"RM Youssef","year":"2014","unstructured":"Youssef, R. M., Korany, M. A. & Afify, M. A. Development of a stability indicating HPLC-DAD method for the simultaneous determination of mometasone furoate and salicylic acid in an ointment matrix. Anal. Methods. 6 (10), 3410\u20133419 (2014).","journal-title":"Anal. Methods"},{"key":"66936_CR15","unstructured":"FDA, U. Bioanalytical method validation guidance for industry (for Drug Evaluation and Research and Center for Veterinary Medicine, 2018). US Department of Health and Human Services Food and Drug Administration Center."},{"issue":"1","key":"66936_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s43088-022-00250-y","volume":"11","author":"AF El-Yazbi","year":"2022","unstructured":"El-Yazbi, A. F. et al. In situ green analytical methods for the rapid and sensitive determination of a newly launched orphan anticancer drug; Tigecycline in infusion bags: comparative study. Beni-Suef Univ. J. Basic. Appl. Sci. 11 (1), 69 (2022).","journal-title":"Beni-Suef Univ. J. Basic. Appl. Sci."},{"issue":"1","key":"66936_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40543-021-00257-7","volume":"12","author":"AF El-Yazbi","year":"2021","unstructured":"El-Yazbi, A. F. et al. Eco-friendly analytical methods for the determination of compounds with disparate spectral overlapping: application to antiviral formulation of sofosbuvir and velpatasvir. J. Anal. Sci. Technol. 12 (1), 7 (2021).","journal-title":"J. Anal. Sci. Technol."},{"key":"66936_CR18","doi-asserted-by":"publisher","first-page":"106073","DOI":"10.1016\/j.microc.2021.106073","volume":"164","author":"AF El-Yazbi","year":"2021","unstructured":"El-Yazbi, A. F. Green methods for the simultaneous analysis of pharmaceutical mixtures present in disparate concentration ranges: Application to antidiabetic mixtures. Microchem. J. 164, 106073 (2021).","journal-title":"Microchem. J."},{"issue":"1","key":"66936_CR19","first-page":"48","volume":"1","author":"AF El-Yazbi","year":"2024","unstructured":"El-Yazbi, A. F. et al. Simple rapid eco-friendly chromatographic analytical method for ten residual cephalosporins in wastewater after their pharmaceutical production. J. Adv. Pharm. Sci. 1 (1), 48\u201357 (2024).","journal-title":"J. Adv. Pharm. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66936-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:53:07Z","timestamp":1787219587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66936-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["66936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-66936-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26178"}}